Search Results for "Suprenza"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Suprenza. Results 1 to 2 of 2 total matches.
See also: phentermine
Contrave - A Combination of Bupropion and Naltrexone for Weight Loss
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014 (Issue 1455)
37.5 mg once/d 62.40
Suprenza (Akrimax) 15, 30, 37.5 mg ODT 15-37.5 mg once/d 110.80
Phentermine ...
The FDA has approved a fixed-dose combination of
the opioid receptor antagonist naltrexone (ReVia, and
others) and the antidepressant and smoking cessation
agent bupropion (Wellbutrin SR, Zyban, and others),
as Contrave (Orexigen/Takeda) for weight loss. The
combination was approved for use as an adjunct to
diet and increased physical activity in patients with a
body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2
and one or more weight-related comorbidities such as
hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled...
Two Drugs for Weight Loss
The Medical Letter on Drugs and Therapeutics • Sep 03, 2012 (Issue 1398)
19.50
Adipex-P (Teva) 37.5 mg tabs 37.5 mg once 62.70
Suprenza (Akrimax) 15, 30 mg ODT 15-30 mg once ...
In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective serotonin 2C receptor agonist. Qsymia (Vivus) is a fixed-dose combination of the weight-loss drug phentermine and an extended-release (ER) formulation of topiramate. The new products are approved for use in obese patients (body mass index [BMI] of ≥30 kg/m2) and for patients who are overweight (BMI ≥27 kg/m2) and have one weight-related risk factor such as hypertension, dyslipidemia or...